A Phase 1b Open-Label, Dose Escalation Study of PRTX-100 in Adult Patients With Persistent/Chronic Immune Thrombocytopenia

Trial Profile

A Phase 1b Open-Label, Dose Escalation Study of PRTX-100 in Adult Patients With Persistent/Chronic Immune Thrombocytopenia

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 13 Nov 2017

At a glance

  • Drugs Staphylococcal-protein-A (Primary)
  • Indications Immune thrombocytopenic purpura
  • Focus Adverse reactions
  • Sponsors Protalex
  • Most Recent Events

    • 13 Nov 2017 According to a Protalex media release, following a planned interim analysis of data from the third dose cohort of the phase Ib study, the company has initiated enrollment in the fourth cohort of this trial.
    • 26 Oct 2017 According to a Protalex media release, results from the higher dose cohorts are anticipated in coming months.
    • 29 Aug 2017 According to a Protalex media release, Protalex has opened seven new clinical trial sites in the U.K.The first U.K. patient has enrolled.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top